Drug intelligence / Profile preview

CF2010

Development stage: Unknown
Lead developer: Zhongke CELFULL
Modality: Small Molecules
Administration: Oral

Overview

CF2010 is a mitochondrial-targeted nutraceutical developed by Zhongke CELFULL Mitochondrial Medicine, specifically formulated to support cardiovascular health. It is part of a specialized pipeline of aging-intervention products that utilize mitochondrial biology to address organ-specific functional decline. CF2010 is currently in the "Launch" phase, indicating it is commercially available as a dietary supplement. The product is designed to optimize cardiac energy metabolism and protect against oxidative stress in heart tissues, likely leveraging key mitochondrial cofactors such as NADH, Coenzyme Q10, or PQQ to enhance ATP production and cellular resilience.

Brand names: CELFULL

Beyond the preview

Go deeper on CF2010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF2010.

Explore the full profile